SCHEMBL25323209

SCHEMBL25323209

Cc1nc(-c2cccc(C#N)c2)n(OCc2ccc(C#N)cc2)c1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
F11 P03951 3/20 0.62
PIN1 Q13526 1/20 0.43
GRIA2 P42262 1/20 0.41
GRIA4 P48058 1/20 0.41
XDH P47989 2/20 0.40
SLC22A12 Q96S37 1/20 0.40
MMP12 P39900 1/20 0.40
MMP13 P45452 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
PTGER4 P35408 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25326951 0.95 F11 (0.61) F11PIN1GRIA2GRIA4XDH
SCHEMBL30771633 0.95 F11 (0.61) F11PIN1GRIA2GRIA4XDH
SCHEMBL25325562 0.95 F11 (0.64) F11PIN1GRIA2GRIA4XDH
SCHEMBL26108172 0.93 F11 (0.59) F11PIN1GRIA2GRIA4
SCHEMBL26106346 0.93 F11 (0.59) F11PIN1GRIA2GRIA4XDH
SCHEMBL26107849 0.93 F11 (0.59) F11PIN1GRIA2GRIA4XDH
SCHEMBL26106750 0.93 F11 (0.64) F11PIN1GRIA2GRIA4XDH
SCHEMBL26107406 0.92 F11 (0.58) F11PIN1GRIA2GRIA4
SCHEMBL26107390 0.92 F11 (0.60) F11PIN1GRIA2GRIA4XDH
SCHEMBL25326711 0.90 F11 (0.52) F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3960734-B1 PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP claimed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US claimed
CN-114105881-A Platelet aggregation inhibitor and preparation method and application thereof 沈阳海诺威医药科技有限公司 2022-03-01 CN claimed
CN-114105881-B Platelet aggregation inhibitor, and preparation method and application thereof 沈阳海诺威医药科技有限公司 2024-01-26 CN disclosed
EP-3960734-B1 PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP disclosed
EP-3960734-B1 PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP disclosed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US disclosed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US disclosed
CN-114105881-A Platelet aggregation inhibitor and preparation method and application thereof 沈阳海诺威医药科技有限公司 2022-03-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof TFPI, F12, TFPI2 F11 7/4885PIN1 3159/4885GRIA2 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.